Columbia Financial management will participate in investor meetings hosted by Piper Sandler on November 17 and 18, 2026. The company will discuss a presentation that will be made available on its Investor Relations website.
Henry Schein announced a voluntary change to its non-GAAP financial reporting to exclude acquisition-related remeasurement gains starting in Q4 2026. Consequently, the company updated its FY2026 non-GAAP diluted EPS guidance to $5.42-$5.48 from $5.50-$5.56 to reflect this accounting adjustment, with no change to its underlying business outlook.
Nektar Therapeutics reaffirmed its financial guidance, stating that its current cash and marketable securities balance of $952.9 million is expected to fund operations into the third quarter of 2028. This runway is intended to support the company through the initial Phase 3 data readouts for its ZENITH AD trials in atopic dermatitis, expected in the summer of 2028.
Elevance Health officers are meeting with investors and analysts to reaffirm the company's full-year 2026 financial guidance. The company continues to expect adjusted shareholders’ earnings of at least $29.00 per diluted share and a benefit expense ratio of 90.2% plus or minus 50 basis points.